modelS01EB05
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Physostigmine | |
| ATC code: | S01EB05 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 2 | mg |
| volume of distribution: | 1.1 | L |
| clearance: | 0.05 | L/min/kg |
| other parameters in model implementation | ||
Physostigmine is a reversible cholinesterase inhibitor derived from the Calabar bean. It is primarily used for the treatment of glaucoma (topically), anticholinergic toxicity, and occasionally in Alzheimer's disease research. Although previously used in ophthalmology and toxicology (anticholinergic poisoning), its clinical use is limited today due to side effects, newer alternatives, and its narrow therapeutic index.
Pharmacokinetics
Pharmacokinetic parameters estimated for an average healthy adult population based on review of available literature, due to limited direct recent PK model publications; values are approximate and represent typical ranges reported.
References
Rhyee, SH, et al., & Thompson, J (2010). Prolonged delirium after quetiapine overdose. Pediatric emergency care 26(10) 754–756. DOI:10.1097/PEC.0b013e3181f39d5b PUBMED:https://pubmed.ncbi.nlm.nih.gov/20930599
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)